Abstract:Objective: To explore the epidemiological characteristics and the risk factors for methamphetamine (MA)-associated psychotic symptoms among MA users in China. Methods: A cross-sectional study was conducted between April, 2012 and October, 2015 among individuals for whom MA was the principal drug of use in a Compulsory Drug Detoxification Center in Beijing, Guangdong Province. Demographic, drug use and psychological characteristics were examined using a specifically-designed questionnaire, the Positive and Negative Syndrome Scale, Barratt Impulsive Scale, Hamilton Anxiety Scale and Beck Depression Inventory. Logistic regression was performed to explore the risk factors for MA-associated psychotic symptoms. Results: A total of 1685 participants were included. Participants were predominantly aged 30 or above, unemployed, and were unmarried Han Chinese men, with limited education. The duration of MA use was more than 3 months in 72.3%. 47.8% reported that the dose of MA use was >= 0.2 g per occasion of use. 11.5% had used two or more synthetic drugs. The prevalence of MA-associated psychotic symptoms was 17.0% among MA users during periods of abstinence. Multiple logistic regression analyses showed that a higher dose (>= 0.2 g per time), a longer duration of MA use (> 3 months) a history of heroin use and a history of tobacco use were associated with MA-associated psychotic symptoms, with adjusted odds ratios (ORs) of 1.96 (95% confidence interval [CI]: 1.40-2.76), 1.98 (95% CI: 1.33-2.96) and 2.45 (95% CI: 1.67-3.60), 1.78 (95% CI: 1.27-2.49) respectively. MA-associated psychotic symptoms were less common among married/cohabitating than unmarried (OR = 0.56; 95% CI: 0.39-0.81), and unemployed than employed (OR = 0.65; 95% CI: 0.47-0.92) individuals. MA users with anxiety and depression symptoms had significantly greater risk for MA-associated psychotic symptoms by 9.70 (6.92-13.59) and 1.90 (1.36-2.65) times respectively. Individuals with higher impulsivity were more likely to have MA-associated psychotic symptoms than those with lower (OR = 2.19; CI: 1.50-3.20). Conclusion: MA-associated psychotic symptoms occurred frequently among MA users in China. The efforts that facilitate drug users' attempts to reduce MA use, abstain from poly-drug use, and control associated psychiatric symptoms and impulsivity should be supported because of their potential contribution to MA-associated psychotic symptoms in this population.

An association study between methamphetamine use disorder with psychosis and polymorphisms in MiRNA.

Significant Linkage and Association Between a Functional (gt)n Polymorphism in Promoter of the N-methyl-D-aspartate Receptor Subunit Gene (GRIN2A) and Schizophrenia.

Association Between Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Methamphetamine Use Disorder: A Meta-Analysis

Decreased Expression of Plasma MicroRNA in Patients with Methamphetamine (MA) Use Disorder.

Polymorphisms in MicroRNA Genes And Genes Involving in NMDAR Signaling and Schizophrenia: A Case-Control Study in Chinese Han Population

Association between two single nucleotide polymorphisms at corresponding microRNA and schizophrenia in a Chinese population

Psychotic symptoms associated increased CpG methylation of metabotropic glutamate receptor 8 gene in Chinese Han males with schizophrenia and methamphetamine induced psychotic disorder: a longitudinal study

The association of FKBP5 polymorphisms with the severity of depressive disorder in patients with methamphetamine use disorders

Epidemiological Characteristics and Risk Factors of Methamphetamine-Associated Psychotic Symptoms

The Vulnerability to Methamphetamine Dependence and Genetics: A Case-Control Study Focusing on Genetic Polymorphisms at Chromosomal Region 5Q31.3

A Polymorphism in the Microrna-30E Precursor Associated with Major Depressive Disorder Risk and P300 Waveform.

A Research Of Methamphetamine Induced Psychosis In 1,430 Individuals With Methamphetamine Use Disorder: Clinical Features And Possible Risk Factors

Relationship Between the Duration of Methamphetamine Use and Psychotic Symptoms: A Two-Year Prospective Cohort Study.

Association Study of GABA System Genes Polymorphisms with Amphetamine-Induced Psychotic Disorder in a Han Chinese Population

Evaluation of Six SNPs of MicroRNA Machinery Genes and Risk of Schizophrenia

Polymorphisms in Microrna Target Sites Influence Susceptibility to Schizophrenia by Altering the Binding of Mirnas to Their Targets

MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia

Association between C-Maf-inducing protein gene rs2287112 polymorphism and schizophrenia

Variants in GABBR1 Gene Are Associated with Methamphetamine Dependence and Two Years’ Relapse after Drug Rehabilitation

Relationship Between Schizophrenia and Changes in the Expression of the Long Non-Coding RNAs Meg3, Miat, Neat1 and Neat2.

Association Study of Monoamine Oxidase A/B Genes and Schizophrenia in Han Chinese